Orthobiologics market seen reaching $8.64 billion by 2030

The orthobiologics devices and equipment market is projected to grow from $5.99 billion in 2025 to $8.64 billion by 2030, driven by aging populations, musculoskeletal disorders and demand for minimally invasive orthopedic treatments. North America led regional sales in 2025, according to The Business Research Company.

Why it matters: - Orthobiologics devices and equipment are used to speed repair of bones, cartilage, tendons and ligaments. - The market is growing as more patients seek treatments for orthopedic conditions and faster recovery. - The category matters for hospitals, orthopedic clinics and regenerative medicine providers looking for non-surgical and minimally invasive options.

What happened: - The Business Research Company released its Orthobiologics Devices And Equipment Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Aug. 20, 2026. - The report projects the market will rise from $5.99 billion in 2025 to $6.36 billion in 2026. - The report forecasts the market will reach $8.64 billion by 2030, implying an 8.0% CAGR over the forecast period. - North America was the largest regional market in 2025, followed by Western Europe.

The details: - Historical growth was driven by more musculoskeletal disorders, more sports injuries, higher orthopedic surgery volumes, broader use of platelet-rich plasma therapies and positive outcomes from bone grafts. - Future growth is expected to come from an aging global population, regenerative medicine innovation, stronger demand for minimally invasive procedures, expanded reimbursement and advances in biomaterials. - Emerging trends include wider adoption of regenerative therapies, more sports injury treatments, increased use of stem cell-based products, stronger demand for non-surgical orthopedic care and more orthopedic clinics worldwide. - Orthobiologic devices are implants made with cells and proteins naturally found in the human body. - These products are designed to accelerate healing and support regrowth of musculoskeletal tissue. - The report says orthobiologics help improve restoration of bone and joint function and can shorten recovery times. - A survey by the Institute for Health Metrics and Evaluation in August 2023 found 15% of people age 30 and older had osteoarthritis in 2023. - The same survey estimated nearly 1 billion people could be affected worldwide by 2050. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics and updated technology and trend analysis. - The company offered a free sample report and the full report through its website. - More information - The full report

Between the lines: - The growth outlook reflects a broader shift toward regenerative and less invasive orthopedic care. - The osteoarthritis figures point to a larger patient pool that could keep demand elevated over the next several years. - North America’s lead suggests the region remains the key commercial market for orthobiologics suppliers.

What's next: - The market is expected to keep expanding through 2030 as aging, injury rates and reimbursement support demand. - Product development is likely to focus on biomaterials, stem cell-based products and other regenerative therapies. - Orthopedic providers may continue adding orthobiologics to treatment pathways as non-surgical options gain ground. - The company's social media